Pfizer, founded in 1849 in Brooklyn, New York, has grown from a fine chemicals producer into one of the world's largest pharmaceutical companies, known for innovations like penicillin mass production, Viagra, and the COVID-19 vaccine, through strategic mergers, acquisitions, and global expansion.
Charles Pfizer and Charles Erhart establish Charles Pfizer & Company in Brooklyn, New York, focusing on fine chemicals. The company's first product is santonin, an antiparasitic. #business #pharma
Pfizer pioneers the production of citric acid from lemons and limes, later innovating fermentation methods. This becomes a major early success. #pharma #innovation
Pfizer builds a new plant in Brooklyn to produce a wide range of chemicals, including tartaric acid and citric acid. The company begins to diversify beyond fine chemicals. #business #expand
John L. Smith takes leadership of Pfizer, overseeing expansion into fermentation technology for citric acid. His tenure modernizes manufacturing processes. #leadership #pharma
The U.S. government asks Pfizer to mass-produce penicillin during World War II. Pfizer develops deep-tank fermentation, revolutionizing antibiotic production. #war #medicine
Pfizer completes a large penicillin plant in Brooklyn, producing enough penicillin to treat all Allied forces. This cements Pfizer's role as a leading pharmaceutical manufacturer. #ww2 #pharma
Pfizer scientists discover oxytetracycline (Terramycin), a broad-spectrum antibiotic. This drug becomes a blockbuster and positions Pfizer as a major drug developer. #innovation #pharma
The FDA approves Terramycin, the first antibiotic developed entirely by Pfizer. It quickly becomes one of the best-selling drugs. #pharma #approval
Pfizer establishes its first overseas subsidiary in Belgium, marking the start of global expansion. International operations grow rapidly. #global #business
Pfizer opens a central research facility in Groton, Connecticut, consolidating R&D efforts. This drives innovation for decades. #research #pharma
Edmund Pratt takes over as CEO, leading Pfizer through a period of international expansion and diversification. He serves until 1991. #leadership #ceo
Feldene, a nonsteroidal anti-inflammatory drug, is launched. It becomes a top-selling painkiller and boosts Pfizer's revenues. #pharma #drug
Pfizer's antidepressant Zoloft receives FDA approval. It becomes one of the most prescribed antidepressants globally. #pharma #mentalhealth
Norvasc, a calcium channel blocker for hypertension, is approved. It becomes a blockbuster, generating over $5 billion annually at its peak. #pharma #hearthealth
Viagra, the first oral treatment for erectile dysfunction, wins FDA approval. It becomes a cultural phenomenon and one of Pfizer's most famous products. #pharma #blockbuster
Pfizer acquires Warner-Lambert for $90 billion, gaining control of blockbuster drug Lipitor (atorvastatin). The merger makes Pfizer the world's largest pharmaceutical company. #merger #pharma
Hank McKinnell succeeds William Steere as Pfizer CEO. He oversees the Pharmacia acquisition and faces challenges from patent expirations. #leadership #ceo
Pfizer completes the $60 billion acquisition of Pharmacia, adding blockbuster drugs like Celebrex and Xalatan. The merger further consolidates Pfizer's market position. #merger #pharma
Sutent, a cancer drug for kidney and gastrointestinal tumors, receives FDA approval. It becomes a key oncology product for Pfizer. #oncology #pharma
Jeff Kindler takes over as Pfizer's CEO, leading cost-cutting and restructuring amid patent cliffs. He resigns abruptly in 2010. #leadership #ceo
Pfizer purchases Wyeth for $68 billion, adding vaccines (Prevnar) and biologics to its portfolio. The deal is the largest in pharma history at the time. #merger #pharma
Ian Read succeeds Jeff Kindler as CEO, focusing on innovation and streamlining operations. He later leads Pfizer's split and major acquisitions. #leadership #ceo
Pfizer divests its capsule manufacturing unit Capsugel to private equity firm KKR for $2.38 billion, part of a strategy to focus on core drug business. #divestiture #business
Pfizer sells its infant nutrition business to Nestlé for $11.85 billion, exiting the niche to concentrate on pharmaceuticals. #divestiture #business
Pfizer spins off its animal health division Zoetis in an IPO, raising $2.6 billion. Zoetis becomes the world's largest pure-play animal health company. #spin off #business
Pfizer withdraws its $118 billion takeover bid for AstraZeneca after failing to secure a deal. The attempt sparks political debate over tax inversions. #merger #failed
Pfizer buys Hospira, a generic injectable drug maker, for $15 billion, expanding its sterile injectables and biosimilars portfolio. #merger #pharma
Pfizer agrees to merge with Allergan in a $160 billion deal to create the world's largest drugmaker. The merger is later blocked by U.S. tax inversion rules. #merger #tax
Pfizer and Allergan call off the merger after the U.S. Treasury tightens rules on tax inversions. Pfizer pays a $150 million termination fee. #merger #failed
Albert Bourla succeeds Ian Read as Pfizer's CEO. He oversees the COVID-19 vaccine development and a series of acquisitions. #leadership #ceo
Pfizer buys Array BioPharma for $11.4 billion, gaining cancer drugs Braftovi and Mektovi for treatment of BRAF-mutant cancers. #merger #oncology
Pfizer merges its consumer health business with GlaxoSmithKline's, creating a joint venture with brands like Advil and Centrum. Pfizer holds a 32% stake. #jointventure #pharma
Pfizer and BioNTech announce their mRNA-based COVID-19 vaccine is 95% effective in Phase 3 trials. It is the first authorized vaccine for COVID-19 in the West. #vaccine #COVID19
The FDA authorizes the Pfizer-BioNTech COVID-19 vaccine for emergency use. Distribution begins within days, marking a turning point in the pandemic. #vaccine #approval
Pfizer buys Arena Pharmaceuticals for $6.7 billion, expanding its immunology pipeline with treatments for inflammatory diseases. #merger #pharma
Pfizer purchases Biohaven Pharmaceutical for $11.6 billion, gaining Nurtec ODT, a migraine treatment. The deal strengthens Pfizer's neuroscience portfolio. #merger #neuroscience
Pfizer reports over $50 billion in combined revenue from COVID-19 vaccine and antiviral Paxlovid in 2022, the highest in its history. #revenue #COVID19
Pfizer announces the acquisition of Seagen, a cancer drugmaker, for $43 billion. The deal closes in December 2023, adding antibody-drug conjugates to Pfizer's portfolio. #merger #oncology
Pfizer reports a significant drop in COVID-19 product sales and announces a $3.5 billion cost-cutting plan, including job reductions. #business #restructuring
Pfizer outlines a strategy to drive growth through oncology, vaccines, and gene editing, aiming to return to revenue growth by 2025. #strategy #pharma